+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 18Years +
All Genders
ID07770841

Evaluating Lower Doses of Oral Semaglutide for Weight Loss in Adults With Overweight or Obesity

Led by Novo Nordisk A/S · Updated on 2026-09-09

450

Participants Needed

62

Research Sites

7 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating how lower doses of oral semaglutide can help reduce body weight in adults with excess body weight, including those with overweight or obesity. The study aims to identify the best lower dose of oral semaglutide for treating weight management. This is a phase 3 clinical trial sponsored by Novo Nordisk AS. Participants will be randomly assigned to receive one of two oral doses of semaglutide or a placebo, all combined with a reduced-calorie diet and increased physical activity. The treatment lasts for 60 weeks, during which participants take the study medication daily. The study compares the effects of these doses on body weight and related health measures. Throughout the 60-week study, participants will be monitored for changes in body weight, waist circumference, blood pressure, blood glucose, cholesterol levels, and inflammation markers. Researchers will assess weight loss success at several thresholds 5%, 10%, 15% and track any adverse events up to week 67. Regular visits will include physical assessments and laboratory tests to evaluate safety and effectiveness over the study period.

CONDITIONS

Brief Title

Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight

Research Team

N

Novo Nordisk

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here